Compare Hims and Hers Health Inc (HIMS) vs Icl Group Ltd (ICL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hims and Hers Health Inc vs Icl Group Ltd — how do they compare? Hims and Hers Health Inc trades at $30.92 (market cap $6.55B), while Icl Group Ltd trades at $5.03 (market cap $6.47B). The key difference: Hims and Hers Health Inc and Icl Group Ltd are close in size by market cap, and Icl Group Ltd pays a 4.11% dividend while Hims and Hers Health Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hims and Hers Health Inc for 21 Days and Icl Group Ltd for 56 Days on average.
| HIMS | ICL | |
|---|---|---|
Market Cap | $6.55B | $6.47B |
Volume | 14,842,814 | 1,387,140 |
Sector | Health | Basic Materials |
52-Week High | $62.76 | $6.84 |
52-Week Low | $14.52 | $4.80 |
Typical Hold Time | 21 Days | 56 Days |
Enterprise Value | $7.25B | $9.11B |
Dividend Yield | — | 4.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hims & Hers Health trades at $30.92, up 4.67% on the day, amid a bearish technical signal and significant legal headwinds from multiple securities class action lawsuits. The stock shows mixed fundamentals with strong revenue growth to $2.35 billion in 2025 but a sharp reversal to a net loss of -$142 million in 2026, reflecting profitability challenges. Valuation ratios appear elevated with a P/E of 57.14 and EV/EBITDA of 205.86, while analyst consensus remains cautiously optimistic with a $32.17 price target.
The outlook is clouded by legal risks and recent earnings misses, though the company's gross margin of 68.43% indicates underlying business strength. Investment opportunity hinges on resolving regulatory scrutiny and returning to profitability, but near-term volatility is likely. Key risks include the FTC lawsuit outcome and sustained negative cash flow, demanding careful risk assessment by investors.
ICL trades at $5.02, down 1.18% today, with a bearish technical signal from moving averages. The company reported Q2 2026 EPS of $0.12, beating estimates, but revenue and net income have declined from 2022 peaks. Valuation appears reasonable with P/E of 20.83 and P/S of 0.84, while analyst consensus is entirely Hold with a $6.08 price target. Recent news highlights dividend strength and cost-transformation initiatives.
The outlook is mixed: earnings beats and dividend yield offer support, but declining profitability and industry headwinds pose challenges. Upside exists if cost cuts and price stabilization materialize, though margin pressure and competitive threats remain key risks for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →About Icl Group Ltd
ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and innovative agriculture solutions (IAS). These segments all contribute to the company's development of agriculture, food, and engineered material products and services. The company mines and manufactures potash and phosphates to be used as ingredients in fertilizers and serve as a component in the pharmaceutical and food additives industries. It is also engaged in industrial additives and materials, including flame retardants, phosphate salts, specialty phosphate blends, purified phosphoric acid, electronic-grade specialty phosphoric acids. Its geographical segments are Europe, Asia, North & South America, and the Rest of the world.
Read more on ICL →
